Clinical Trial Update: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the combination of elacestrant and everolimus in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations that progresse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Esr1-mutant Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)
• Everolimus (everolimus)

Snippet

Sponsor: MedSIR | Conditions: Advanced Breast Cancer, ER-positive Breast Cancer | Phase 3 | Status: RECRUITING